Lactobacillus plantarum for adults with mild psoriasis
Evaluating the Safety and Efficacy of Lactobacillus Plantarum in Treating Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
PHASE2 · Shenzhen People's Hospital · NCT07194200
This study will test whether taking Lactobacillus plantarum or an inactivated version can improve skin symptoms in adults aged 18–60 with mild psoriasis.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 184 (estimated) |
| Ages | 16 Years to 60 Years |
| Sex | All |
| Sponsor | Shenzhen People's Hospital (other) |
| Locations | 1 site (Shenzhen, Guangdong) |
| Trial ID | NCT07194200 on ClinicalTrials.gov |
What this trial studies
This Phase 2, randomized, double-blind, placebo-controlled trial at Shenzhen People's Hospital will assign adults with mild psoriasis (PASI <10) to receive live Lactobacillus plantarum, inactivated Lactobacillus plantarum, or placebo. Participants must be 18–60 years old, in good general health, and off other medications for at least six months. The trial will monitor safety and changes in psoriasis severity and skin-related outcomes over the treatment period. The study is designed to explore whether modifying the skin microbiome can reduce inflammation and improve the skin barrier in psoriasis.
Who should consider this trial
Good fit: Adults 18–60 in good general health with mild plaque psoriasis (PASI <10), no recent medication use, and no other inflammatory skin or serious systemic diseases are the intended participants.
Not a fit: Patients with moderate-to-severe psoriasis, other psoriasis subtypes, active skin infections, major comorbidities, or who cannot comply with study procedures are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, this approach could provide a microbiome-targeted treatment that reduces psoriasis symptoms with potentially fewer systemic side effects than conventional systemic therapies.
How similar studies have performed: Early preclinical work and small clinical reports suggest microbiome modulation may help psoriasis, but randomized controlled evidence is still limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Reference to Psoriasis Area and Severity Index (PASI) score \< 10 Patients have been informed of the study details, voluntarily participate, and have signed the informed consent form; Aged 18-60 years with good general health status; No use of any medications within 6 months; No various inflammatory or immune skin diseases, no local infections, and no neuromuscular diseases. Exclusion Criteria: * Patients with other types of psoriasis or severe psoriasis; Those in the active phase of skin diseases or with other serious diseases; Other situations deemed unsuitable for enrollment by the researchers, such as subjects who are untrustworthy, unable to accept or understand the study assessments.
Where this trial is running
Shenzhen, Guangdong
- Shenzhen People's Hospital — Shenzhen, Guangdong, China (RECRUITING)
Study contacts
- Study coordinator: Jianglin Zhang
- Email: zhang.jianglin@szgospital.com
- Phone: +86 13873143466
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Psoriasis, Lactobacillus Plantarum, psoriasis, Lactobacillus plantarum